Researcher.Life Logo

Translational Neurodegeneration : Impact Factor & More

eISSN: 2047-9158pISSN: 2047-9158
JournalOpen Access

Key Metrics

CiteScore
12
Impact Factor
10 - 15
SJR
Q1Neurology (clinical)
SNIP
1.76
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Translational Neurodegeneration

Translational Neurodegeneration Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2490 | USD 2890 | GBP 2090
Publication Time10
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 10
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Translational Neurodegeneration ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Translational Neurodegeneration

Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons
  • 18 May 2026
  • Translational Neurodegeneration
Calbindin-D28k deficiency mediates tau-driven hippocampal hyperexcitement and cognitive impairment
  • 12 May 2026
  • Translational Neurodegeneration
The emerging role and therapeutic targeting of autophagy-lysosome pathway in the pathogenesis of Parkinson's disease.
  • 7 May 2026
  • Translational neurodegeneration
A new dawn for Parkinson's disease: commentary on the emergence of stem cell-based therapies.
  • 29 Apr 2026
  • Translational neurodegeneration
The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.
  • 27 Apr 2026
  • Translational neurodegeneration
N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease.
  • 27 Apr 2026
  • Translational neurodegeneration
Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons
  • 18 May 2026
  • Translational Neurodegeneration
Calbindin-D28k deficiency mediates tau-driven hippocampal hyperexcitement and cognitive impairment
  • 12 May 2026
  • Translational Neurodegeneration
The emerging role and therapeutic targeting of autophagy-lysosome pathway in the pathogenesis of Parkinson's disease.
  • 7 May 2026
  • Translational neurodegeneration
A new dawn for Parkinson's disease: commentary on the emergence of stem cell-based therapies.
  • 29 Apr 2026
  • Translational neurodegeneration
The Drp1-CoQ10-Coa6-ETC axis represents a therapeutic potential for working memory impairment caused by neuronal mitochondrial dysfunction.
  • 27 Apr 2026
  • Translational neurodegeneration
N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease.
  • 27 Apr 2026
  • Translational neurodegeneration

FAQs on Translational Neurodegeneration